Literature DB >> 28426528

Comparative Analysis of Multicolor Flow Cytometry and Immunohistochemistry for the Detection of Disseminated Tumor Cells.

Eszter Szánthó1, Bettina Kárai1, Gergely Ivády1, Judit Bedekovics2, István Szegedi3, Miklós Petrás4, György Ujj5, Anikó Ujfalusi1, Csongor Kiss3, János Kappelmayer1, Zsuzsanna Hevessy1.   

Abstract

Disseminating cells of a primary solid tumor may represent the origin of metastases and relapses. We aimed at comparing the diagnostic efficacy of multicolor flow cytometry (MFC) and morphology/immunohistochemistry (IHC) in the detection of disseminated tumor cells in the bone marrow (BM) and body fluids of patients with solid tumors, and in pediatric neuroblastoma cases. We investigated 72 samples retrospecively from 50 patients by MFC. Morphology/IHC data were available in 48 cases. In the first cohort, 36 samples derived from 34 patients with various forms of suspected and proven solid tumors and in the second cohort, 36 samples of 16 children with suspected and proven neuroblastoma were analyzed at diagnosis or during follow-up in a 4-color setting by MFC, and the results were compared with those obtained by IHC. In the group of various solid tumors, we found 91% concordance between IHC and MFC, and it was 65% in the neuroblastoma group, and 77% overall. Detection of disseminated tumor cells was found to be more effective by MFC in de novo neuroblastoma samples (100% vs. 86%). The advantage of MFC was even more pronounced when minimal residual disease was evaluated (efficacy, 92% vs. 68%). In contrast, efficacy of IHC was 100% in the group of various solid tumors, whereas it was 91% for MFC. We conclude that MFC and IHC are both essential tools for examining infiltration of BM and body fluids by disseminating solid tumor cells. In the case of neuroblastoma, however, minimal residual disease detection by MFC in a hypoplastic/aplastic BM environment was more effective than IHC, as considerably more cells could be analyzed.

Entities:  

Mesh:

Year:  2018        PMID: 28426528     DOI: 10.1097/PAI.0000000000000519

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  5 in total

1.  Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues.

Authors:  Noah Sorrelle; Debolina Ganguly; Adrian T A Dominguez; Yuqing Zhang; Huocong Huang; Lekh N Dahal; Natalie Burton; Arturas Ziemys; Rolf A Brekken
Journal:  J Immunol       Date:  2018-12-03       Impact factor: 5.422

2.  Diagnosis of Acute Leukemia by Multiparameter Flow Cytometry with the Assistance of Artificial Intelligence.

Authors:  Pengqiang Zhong; Mengzhi Hong; Huanyu He; Jiang Zhang; Yaoming Chen; Zhigang Wang; Peisong Chen; Juan Ouyang
Journal:  Diagnostics (Basel)       Date:  2022-03-28

3.  Flow cytometry of bone marrow aspirates from neuroblastoma patients is a highly sensitive technique for quantification of low-level neuroblastoma.

Authors:  Neha Jain; Shaista Sattar; Sarah Inglott; Susan Burchill; Jonathan Fisher; Andreea-Madalina Serban; Rebecca Thomas; Chris Connor; Niharendu Ghara; Tanzina Chowdhury; Catriona Duncan; Giuseppe Barone; John Anderson
Journal:  F1000Res       Date:  2021-09-21

4.  Flow cytometry-based analysis of tumor-leukocyte ratios in peritoneal fluid from patients with advanced gastric cancer.

Authors:  Kazuya Takahashi; Kentaro Kurashina; Shin Saito; Rihito Kanamaru; Hideyuki Ohzawa; Hironori Yamaguchi; Hideyo Miyato; Yoshinori Hosoya; Alan Kawarai Lefor; Naohiro Sata; Joji Kitayama
Journal:  Cytometry B Clin Cytom       Date:  2020-12-04       Impact factor: 3.248

5.  Microbial Regulation of Enteric Eosinophils and Its Impact on Tissue Remodeling and Th2 Immunity.

Authors:  Rodrigo Jiménez-Saiz; Varun C Anipindi; Heather Galipeau; Yosef Ellenbogen; Roopali Chaudhary; Joshua F Koenig; Melissa E Gordon; Tina D Walker; Talveer S Mandur; Soumeya Abed; Alison Humbles; Derek K Chu; Jonas Erjefält; Kjetil Ask; Elena F Verdú; Manel Jordana
Journal:  Front Immunol       Date:  2020-02-13       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.